Results 91 to 100 of about 36,843 (223)

Dietary melatonin and its benefits on cardiovascular disease

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiovascular disease remains the leading cause of mortality globally, with a disproportionate burden in low‐ and middle‐income countries. Melatonin, a hormone primarily produced by the pineal gland, exhibits notable antioxidant, anti‐inflammatory and immunomodulatory properties that may confer cardiovascular benefits.
Karabo Tisane   +2 more
wiley   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams   +3 more
wiley   +1 more source

A rare presentation of haemobilia with acute pancreatitis: a case report

open access: yesBMC Surgery
Background Haemobilia, caused by hepatic artery aneurysms leading to acute pancreatitis is a rare presentation. Pancreatitis is hypothesized to result from a similar mechanism to gallstone obstruction at the ampulla of Vater.
Malith Nandasena   +7 more
doaj   +1 more source

Cardiometabolic Protein Profile Changes During Gender‐Affirming Hormone Therapy: A Prospective Clinical Study

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Cardiovascular disease (CVD) risk is elevated in transgender individuals during gender‐affirming hormone therapy (GAHT) with expected different mechanisms between T‐ and E2‐based GAHT. We investigated prospective changes in cardiometabolic proteins relating to complement, inflammation, and transport during GAHT.
Emilie Bukh Madsen   +12 more
wiley   +1 more source

Histopathologic Characterization of Cutaneous Oxalosis Mimicking Calciphylaxis: Diagnostic Pitfalls and Polarized Light Evaluation

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous oxalosis is an uncommon manifestation of primary hyperoxalosis, which can often resemble other cutaneous manifestations of end stage renal disease (ESRD), particularly calciphylaxis. We report the case of a 46 year old female with primary hyperoxaluria type one (PH1) believed to be well‐controlled on lumasiran, a small interfering ...
Shrina Patel   +3 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou   +5 more
wiley   +1 more source

Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH): An Algorithmic Approach in an Era of New Treatments

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder caused by a defect of glycosylphosphatidyl‐anchored proteins, leading to an uncontrolled complement‐mediated hemolysis. The advent of complement inhibitors in clinical practice radically changed patients' outcomes and survival.
Bruno Fattizzo   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy